PT - JOURNAL ARTICLE AU - Matthew K. Wynia AU - Laurel E. Beaty AU - Tellen D. Bennett AU - Nichole E. Carlson AU - Christopher B. Davis AU - Bethany M. Kwan AU - David A. Mayer AU - Toan C. Ong AU - Seth Russell AU - Jeffrey Steele AU - Heather R. Stocker AU - Adane F. Wogu AU - Richard D. Zane AU - Ronald J. Sokol AU - Adit A. Ginde TI - Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients AID - 10.1101/2022.01.09.22268963 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.09.22268963 4099 - http://medrxiv.org/content/early/2022/01/11/2022.01.09.22268963.short 4100 - http://medrxiv.org/content/early/2022/01/11/2022.01.09.22268963.full AB - Background Neutralizing monoclonal antibodies (mAbs) are authorized for early symptomatic COVID-19 patients. Whether mAbs are effective against the SARS-CoV-2 Delta variant, among vaccinated patients, or for prevention of mortality remains unknown.Objective To evaluate the effectiveness of mAb treatment in preventing progression to severe disease during the Delta phase of the pandemic and based on key baseline risk factors.Design, Setting, and Patients Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from November 2020-October 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data. Using propensity matching, we selected approximately 2.5 patients not receiving mAbs for each patient who received mAbs.Exposure Neutralizing mAb treatment under emergency use authorizationMain Outcomes The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization.Results Of 36,077 patients with SARS-CoV-2 infection, 2,675 receiving mAbs were matched to 6,677 not receiving mAbs. Compared to mAb-untreated patients, mAb-treated patients had lower all-cause hospitalization (4.0% vs 7.7%; adjusted OR 0.48, 95%CI 0.38-0.60) and all-cause mortality (0.1% vs. 0.9%; adjusted OR 0.11, 95%CI 0.03-0.29) to day 28; differences persisted to day 90. Among hospitalized patients, mAb-treated patients had shorter hospital length of stay (5.8 vs. 8.5 days) and lower risk of mechanical ventilation (4.6% vs. 16.6%). Relative effectiveness was similar in preventing hospitalizations during the Delta variant phase (adjusted OR 0.35, 95%CI 0.25-0.50) and across subgroups. Lower number-needed-to-treat (NNT) to prevent hospitalization were observed for subgroups with higher baseline risk of hospitalization (e.g., multiple comorbidities (NNT=17) and not fully vaccinated (NNT=24) vs. no comorbidities (NNT=88) and fully vaccinated (NNT=81).Conclusion Real-world evidence demonstrated mAb effectiveness in reducing hospitalization among COVID-19 outpatients, including during the Delta variant phase, and conferred an overall 89% reduction in 28-day mortality. Early outpatient treatment with mAbs should be prioritized, especially for individuals with highest risk for hospitalization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Institutes of Health / National Center for Advancing Translational Sciences grants UL1TR002525, UL1TR002535-03S3 and UL1TR002535-04S2.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Colorado Multiple Institutional Review Board with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study may be made available upon reasonable request to the corresponding author.